Analyst Ratings For Catalyst Pharmaceuticals (NASDAQ:CPRX)
Today, HC Wainwright reiterated its Buy rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) with a price target of $6.00.
Some recent analyst ratings include
- 3/15/2018-HC Wainwright Reiterated Rating of Buy.
- 11/29/2017-SunTrust Banks Reiterated Rating of Buy.
Recent Insider Trading Activity For Catalyst Pharmaceuticals (NASDAQ:CPRX)
Catalyst Pharmaceuticals (NASDAQ:CPRX) has insider ownership of 9.60% and institutional ownership of 54.73%.
- On 9/5/2017 Patrick J Mcenany, Insider, bought 20,000 with an average share price of $2.58 per share and the total transaction amounting to $51,600.00.
- On 7/12/2016 Charles B O’keeffe, Director, bought 20,000 with an average share price of $0.81 per share and the total transaction amounting to $16,200.00.
- On 6/17/2016 Philip H Coelho, Director, bought 15,000 with an average share price of $0.76 per share and the total transaction amounting to $11,400.00.
- On 6/14/2016 Donald A Denkhaus, Director, bought 50,000 with an average share price of $0.65 per share and the total transaction amounting to $32,500.00.
- On 6/14/2016 Patrick J Mcenany, CEO, bought 105,300 with an average share price of $0.65 per share and the total transaction amounting to $68,445.00.
- On 4/26/2016 Charles B O’keeffe, Director, bought 20,000 with an average share price of $0.60 per share and the total transaction amounting to $12,000.00.
- On 4/26/2016 Patrick J Mcenany, CEO, bought 50,000 with an average share price of $0.65 per share and the total transaction amounting to $32,500.00.
Recent Trading Activity for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Shares of Catalyst Pharmaceuticals closed the previous trading session at with 537707 shares trading hands.